David L Porter

4PUBLICATIONS
42CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Apr 03, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic Dysfunction.

In-Young Jung, Robert L Bartoszek, Andrew J Rech

|Jul 15, 2022
Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies.

Yimei Li, Wei-Ting Hwang, Shannon L Maude

|May 18, 2022
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.

Daanish Hoda, Robert Richards, Edward A Faber

|Jan 28, 2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Joseph A Fraietta, Kyle A Beckwith, Prachi R Patel

Pageof 1